Analyzing Retrophin (RTRX) & Microbot Medical (MBOT)

Retrophin (NASDAQ: RTRX) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk and Volatility

Retrophin has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500.

Valuation & Earnings

This table compares Retrophin and Microbot Medical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Retrophin $133.59 million 6.28 -$47.90 million ($1.51) -14.13
Microbot Medical $120,000.00 313.29 -$9.66 million N/A N/A

Microbot Medical has higher revenue, but lower earnings than Retrophin.

Profitability

This table compares Retrophin and Microbot Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Retrophin -33.79% -10.13% -5.94%
Microbot Medical N/A -270.62% -188.83%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Retrophin and Microbot Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Retrophin 0 0 3 0 3.00
Microbot Medical 0 0 0 0 N/A

Retrophin presently has a consensus target price of $36.00, indicating a potential upside of 68.70%. Microbot Medical has a consensus target price of $1.15, indicating a potential upside of 6.48%. Given Retrophin’s higher possible upside, equities analysts clearly believe Retrophin is more favorable than Microbot Medical.

Institutional & Insider Ownership

4.7% of Microbot Medical shares are owned by institutional investors. 2.4% of Retrophin shares are owned by insiders. Comparatively, 31.8% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Retrophin beats Microbot Medical on 6 of the 11 factors compared between the two stocks.

Retrophin Company Profile

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Microbot Medical Company Profile

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply